Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2022 | Neuronal network hyperexcitability as a biomarker in Alzheimer’s disease

Sean Tok, PhD Candidate, Janssen Inc., Beerse, Belgium, talks on the potential of neuronal network hyperexcitability as a biomarker in Alzheimer’s disease (AD). Neuronal network hyperexcitability is a key component of AD and is thought to begin during the early stages of disease. Emerging evidence suggests that brain network alterations begin even decades before the symptomatic onset of AD. It therefore seems plausible that hyperexcitability could be used as a marker to test therapeutic efficacy in clinical trials and to track disease progression. Network hyperexcitability may also represent a targetable disease mechanism through which network dysfunction could be modulated. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.


Sean Tok reports the following disclosures: Janssen Pharmaceuticals